Aadi Bioscience, Inc.

AADI

US00032Q1040

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
1.33 ^USD	-5.00%		-18.40%	-34.16%

Jul. 01	Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell 3000E Value Index	CI
Jul. 01	Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell 2000 Value Index	CI

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell 2500 Index

July 30, 2024

Latest news about Aadi Bioscience, Inc.

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell 3000E Value Index	Jun. 30	CI
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell 2000 Value Index	Jun. 30	CI
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell 3000 Value Index	Jun. 30	CI
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell 3000E Index	Jun. 30	CI
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell 2500 Value Index	Jun. 30	CI
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Small Cap Completeness Index	Jun. 30	CI
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell 2500 Index	Jun. 30	CI
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell 3000 Index	Jun. 30	CI
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell 2000 Index	Jun. 30	CI
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Small Cap Comp Value Index	Jun. 30	CI
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology Annual Meeting	May. 23	CI
Aadi Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Earnings Flash (AADI) AADI BIOSCIENCE Reports Q1 Revenue $5.4M	May. 08	MT
Transcript : Aadi Bioscience, Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Transcript : Aadi Bioscience, Inc., Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $6.3M	Mar. 13	MT
Aadi Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 13	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
North American Morning Briefing : Stock Futures Hover At Start of Busy Week	Mar. 04	DJ
Aadi Bioscience Reports Supportive Data from Tumor Treatment Trial -- Shares Jump After Hours	Mar. 01	MT
North American Morning Briefing : Stock Futures -2-	Dec. 18	DJ
Sector Update: Health Care Stocks Retreating Late Afternoon	Dec. 15	MT
Top Midday Decliners	Dec. 15	MT
Piper Sandler Cuts Aadi Bioscience's Price Target to $5 From $30, Keeps Overweight Rating	Dec. 15	MT
Wall Street Set to Open Narrowly Mixed Ahead of PMI, Industrial Production Data	Dec. 15	MT

Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing precision therapies for cancers with alterations in the mammalian target of rapamycin (mTOR) pathway, a regulator of cell growth and cancer progression. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. It has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations.

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Aadi Bioscience, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.33 USD

Average target price

11 USD

Spread / Average Target

+727.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
AADI BIOSCIENCE, INC.	-34.16%	34.38M
CSL LIMITED	+4.57%	96.72B
SAMSUNG BIOLOGICS CO.,LTD.	+5.66%	41.43B
BIOGEN INC.	-12.80%	32.7B
UCB	+80.99%	29.06B
BIOMARIN PHARMACEUTICAL INC.	-15.53%	15.38B
INCYTE CORPORATION	-8.70%	12.97B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.22%	11.36B
ALTEOGEN INC.	+183.25%	9.9B
SWEDISH ORPHAN BIOVITRUM AB	+3.60%	8.93B

Biopharmaceuticals